Corcept Therapeutics officer sells 8,333 shares

Q: What were CORT officer Roberto Wandenkolk Vieira's stock sales on October 2, 2026?

Roberto Wandenkolk Vieira reported three sales: 1,100 shares at a weighted average of $114.5205 per share, within $114.03 to $114.90; 2,086 shares at $115.7298, within $115.16 to $116.04; and 5,147 shares at $116.5850, within $116.24 to $117.22.

The three reported sales by Corcept Therapeutics' President, Oncology, were made under a 10b5-1 plan adopted before the officer appointment.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics' President, Oncology, Roberto Wandenkolk Vieira, exercised options for 8,333 common shares at $21.63 per share on October 2, 2026. The reported stock-option position after the exercise was 133,334 shares.

Three common-stock sales were reported that day: 1,100 shares at a weighted average of $114.5205 per share, 2,086 at $115.7298, and 5,147 at $116.5850. The sales were made under a 10b5-1 plan adopted June 17, 2026, before he was appointed an officer.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,333 shares ($787K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Vieira Roberto Wandenkolk

Role President, Oncology

Sold 8,333 shs ($967K)

Approx. gross sale proceeds $967K

Approx. exercise cost $180K

Approx. pre-tax spread $787K

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) ^F6	8,333	$0.00	$0.00
Exercise	Common Stock ^F1	8,333	$21.63	$180K
Sale	Common Stock ^{F2, F3, F1}	1,100	$114.5205	$126K
Sale	Common Stock ^{F2, F4, F1}	2,086	$115.7298	$241K
Sale	Common Stock ^{F2, F5, F1}	5,147	$116.585	$600K

Holdings After Transaction: Stock option (right to buy) — 133,334 contracts (Direct); Common Stock — 3,946 shares (Direct)

Footnotes (6)

F1. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

Key Figures

Option exercise: 8,333 underlying common shares at $21.63 per share Reported stock-option position: 133,334 shares Common-stock sale: 1,100 shares at weighted average $114.5205 per share +2 more

5 metrics

Option exercise 8,333 underlying common shares at $21.63 per share October 2, 2026

Reported stock-option position 133,334 shares After the October 2, 2026 exercise

Common-stock sale 1,100 shares at weighted average $114.5205 per share October 2, 2026

Common-stock sale 2,086 shares at weighted average $115.7298 per share October 2, 2026

Common-stock sale 5,147 shares at weighted average $116.5850 per share October 2, 2026

Key Terms

10b5-1 plan, weighted average sale price, restricted stock awards, vested and exercisable

4 terms

10b5-1 plan regulatory

"made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

restricted stock awards financial

"shares underlying unvested restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

vested and exercisable technical

"until fully vested and exercisable on January 29, 2028"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CORT officer Roberto Wandenkolk Vieira's stock sales on October 2, 2026?

Roberto Wandenkolk Vieira reported three sales: 1,100 shares at a weighted average of $114.5205 per share, within $114.03 to $114.90; 2,086 shares at $115.7298, within $115.16 to $116.04; and 5,147 shares at $116.5850, within $116.24 to $117.22.

What are the vesting terms for Roberto Wandenkolk Vieira's CORT stock option?

The option vested and became exercisable for 25% of its underlying shares on January 29, 2025. The remaining shares vest and become exercisable ratably each month over 36 consecutive months, until fully vested and exercisable on January 29, 2028, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/05/2026 - 07:59 PM Accepted by SEC EDGAR 10/05/2026 - 07:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieira Roberto Wandenkolk

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, Oncology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/02/2026		M		8,333	A	$21.63	12,279⁽¹⁾	D
Common Stock	10/02/2026		S⁽²⁾		1,100	D	$114.5205⁽³⁾	11,179⁽¹⁾	D
Common Stock	10/02/2026		S⁽²⁾		2,086	D	$115.7298⁽⁴⁾	9,093⁽¹⁾	D
Common Stock	10/02/2026		S⁽²⁾		5,147	D	$116.585⁽⁵⁾	3,946⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$21.63	10/02/2026		M			8,333	⁽⁶⁾	02/01/2034	Common Stock	8,333	$0.00	133,334	D

Explanation of Responses:

1. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Roberto Wandenkolk Vieira .	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR